Bayer AG (ADR)

• Will This Company Dominate the Multiple Sclerosis Market?

  By Kanak Kanti - June 12, 2013 | Tickers: BAYRY.PK, BIIB, TEVA

  With one product already on the market, one recently approved and four more in various stages of clinical development, Biogen Idec (NASDAQ: BIIB) has a very strong presence in the multiple sclerosis space. Multiple sclerosis is a debilitating disease that affects 2.5 million people worldwide, and 400,000 Americans annually, according to WebMD.

  Making Biogen Idec's position even stronger, the company recently submitted a biologics license application more »

• A Strategic Healthcare Deal With an Expensive Price Tag

  By Anh HOANG - May 8, 2013 | Tickers: BAYRY.PK, CPTS, HOLX

  Recently, Bayer AG (NASDAQOTH: BAYRY.PK) has announced that it will acquire Conceptus (NASDAQ: CPTS) at an average of $31 per share in cash, with a total transaction value of $1.1 billion. The offering price represented a 20% premium to its trading level of $25.90 on April 26. Conceptus’ shareholders must be quite happy, as Conceptus’ share price has experienced a sweet gain of as much as 47.7 more »

• The Oncology Stock to Buy Today

  By Shas Dey - March 29, 2013 | Tickers: AVEO, BAYRY.PK, CELG, ONXX

  Onyx Pharmaceuticals (NASDAQ: ONXX) is trying to shrug off its dependency on partners, and transform itself from a royalty and drug-development company into a full-fledged biopharmaceutical company. This was evident when the company’s CEO, N. Anthony Coles, said at an investors meet that, "The way to build a successful, sustainable business is through acquisitions, either companies or products -- even licensing deals."

  Onyx’s CEO has things going for him more »

• Consider these International Health Care Stocks

  By Robert Ciura - January 30, 2013 | Tickers: AZN, BAYRY.PK, NVS, SNY

  Companies in the health care sector provide essentials to both customers and investors: namely, their products and their dividends.  One of the things I look for in a company is products that people need no matter the prevailing economic climate.  Medicines and consumer health products certainly fit that bill.  While the U.S-based health care giants are well-known to most investors, the following is a list of international competitors in more »

• Nutrition's Market Domination with the Schiff-Beckitt Merger

  By Josef Ray Dagatan - December 5, 2012 | Tickers: BAYRY.PK, RBGPF, SHF

  Schiff Nutrition International (NYSE: SHF) is known to be one of the leading companies that manufactures, develops, distributes, markets, and sells sports nutrition products, vitamins, and other nutritional supplements, under different brand names like MegaRed, Move Free, Airborne, Tiger's Milk, Digestive Advantage, and Schiff Vitamins. It offers products mainly for care for joints, immunological support, digestive health, and health of the heart. By supporting and developing new and stronger more »

• The Bayer-Schiff Deal is Just the Start

  By Tony Daltorio - November 2, 2012 | Tickers: BAYRY.PK, KO, PFE, SNY, SHF

  Pharmaceutical companies are finding that the old model of researching, developing and marketing drugs is no longer working. The competition from generic drug makers (after patent expirations) is just too tough. So the pharmaceutical companies in recent years have gone on a diversification spree, in search of more stable sources of income. This has led the firms to buying companies in diverse areas such as animal health and consumer health more »

• Would You Trade Shoulder Pain for a Heart Attack?

  By Chris Marasco - September 12, 2012 | Tickers: BAYRY.PK, BMY, MRK, PFE

  The hot industries get all the press.  The media keeps explaining how social media allows companies to have one-on-one relationships with customers and to target each customer directly.  This is why social media expert Gary Vaynerchuk says that marketing is about to get really, really hard.

  But the personalization trend is across the board.  Health care, for instance, is quickly moving (for health care this means years) toward personalized medicine more »

• Regeneron's Vision for the Future

  By Jonathan Lim - August 27, 2012 | Tickers: ALPMY.PK, BAYRY.PK, REGN, RHHBY, SNY

  "Great company, but not at that price" is a line I use a lot these days. It sure can be tempting to deviate from a value-focused strategy, especially when all sorts of glamorous growth stories are commanding billion-dollar valuations and your Benjamin Graham cigarette-butt stocks aren’t featured on CNBC every day and aren’t sending you glossy annual reports full of exciting news. But I’m managing to stick more »

• Trius Therapeutics Holds Steady and Reports Positive Financials

  By John Eastman - August 10, 2012 | Tickers: BAYRY.PK, TSRX

  There is something to be said for slow, steady, and cerebral; especially, if you are invested in a biopharmaceutical firm. This industry does not turn out products overnight. It is a slow, long and grueling process of development, clinical trial testing, FDA maneuvering, safe (GMP) good manufacturing practice production, effective distributing and marketing, and obtaining key partners. And then there is the money! Costs of clinical trial testing are exorbitant more »

• U.S. Biofirms Progress Offshore with Diverse Deals

  By John Eastman - May 14, 2012 | Tickers: BAYRY.PK, TSRX

  The U.S. Federal Drug Agency (FDA) is known to be one of the best in the world for screening, approving, and the regulation of safe and effective drugs for its population. The agency is quite diverse, with divisions allocated for various medical conditions and diseases, oncology, hematology, and ophthalmology, among others. Companies in the biotech, biopharmaceutical, and even big pharma industries generally report receiving cooperation and advice from the more »